8 stories mentioning SHA:600062Updated 4d ago
Every FINWIRES story that references SHA:600062, newest first.
China Resources Double-Crane Pharmaceutical (SHA:600062) plans to acquire 23.5% of Lier Chemical for an aggregate consideration of 5.66 billion yuan, according to a Shanghai bourse filing on Thursday.About 20% and 3.5% of the herbicide maker will be bought from Jiuyuan Group and Huacai Technology, respectively.The pharmaceutical company's shares dropped 4% during the morning trade.
China Resources Pharmaceutical's (HKG:3320) indirect subsidiary China Resources Double-Crane Pharmaceutical (SHA:600062) has emerged as the top bidder to acquire a 23.5% stake in Lier Chemical (SHE:002258), according to a Wednesday Hong Kong bourse filing.Double-Crane ranked first in a public bidding process for 188.1 million shares being sold by Sichuan Jiuyuan Investment and Sichuan Huacai Technology. It currently holds no interest in Lier Chemical, the filing said.The company said the potential acquisition would support its synthetic biology strategy by strengthening its presence in crop and animal protection, one of its four core focus areas.The transaction remains subject to the execution of definitive agreements and satisfaction of customary conditions, and may or may not proceed.
China Resources Double-Crane Pharmaceutical's (SHA:600062) unit, China Resources Double-Crane Xiangzhong Pharmaceutical (Hunan), received a certificate of suitability from the European Union's drug regulator for its sodium valproate activity pharmaceutical ingredient, according to a Shanghai bourse filing on Thursday.The drug is used to treat neurological and psychiatric disorders, primarily epilepsy and mania associated with bipolar disorder.
China Resources Double-Crane Pharmaceutical (SHA:600062) obtained drug registration from China's medical products administrator for its compound polyethylene glycol electrolytes powder.The drug is used to treat chronic constipation and fecal impaction in children, according to a Thursday filing with the Shanghai bourse.Shares of the pharmaceutical company were up 1% Thursday.
China Resources Double-Crane Pharmaceutical (SHA:600062) said its subsidiaries have received drug registration certificates from China's National Medical Products Administration for three products.The approved drugs are linagliptin and metformin hydrochloride tablets, progesterone injection and vortioxetine hydrobromide tablets, according to a bourse filing on Wednesday.
China Resources Double-Crane Pharmaceutical (SHA:600062) unit CR Saike obtained drug registration from China's drug regulator for ezetimibe tablets.The drug is used to treat primary hypercholesterolemia, homozygous familial hypercholesterolaemia, and sitosterolemia, according to a Tuesday filing with the Shanghai bourse.Shares of the pharmaceutical company were down 1% in recent trade.
China Resources Double-Crane Pharmaceutical (SHA:600062) posted net profit of 501.4 million yuan for the first quarter of 2026, down from 522.7 million yuan a year earlier, according to an April 24 Hong Kong bourse filing by parent China Resources Pharmaceutical (HKG:3320).Revenue fell to 2.81 billion yuan from 3.08 billion yuan in the prior year period.
China Resources Double-Crane Pharmaceutical (SHA:600062) received approval from the National Medical Products Administration to change the marketing authorization holder of dienogest tablets, according to a Shanghai bourse filing on Wednesday.Under the approved supplementary application, the pharmaceutical company's subsidiary, CR Zizhu Pharmaceutical, becomes the marketing authorization holder, as well as the manufacturer of the endometriosis drug.
